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Introduction
Wheat is the most widely cultivated cereal and is extensively 
used in food products. Wheat allergy is diagnosed, based on 
oral food challenge (OFC), in 0.48% in children in a recently 
published paper.1,2 Although the standard therapy for food 
allergy is strict avoidance of the incriminated food, this 
approach severely affects the patient’s quality of life with a per-
sisting risk of an accidental allergic reaction through inadvert-
ent contact.3 Oral immunotherapy (OIT), performed by oral 
exposure to increasing doses of the offending food substance, is 
currently seen as a promising option for the treatment of food 
allergies. However, one major drawback of OIT using standard, 
allergenic food products, is the possibility of severe allergic 
reactions, which are observed mainly during the initial escala-
tion phase.3,4 We aimed at designing a less allergenic but still 
immunogenic wheat-based product to be used in OIT. Wheat 
allergic patients should tolerate this product better than intact 
whey proteins, hence reducing the number and severity of 
adverse events observed during the initial escalation phase of 
an OIT trial and allowing to reduce the timing needed to reach 
the maintenance dose and as a consequence the number of days 
spent in hospital.
We therefore developed low-allergenic wheat-based cere-
als, by partial enzymatic hydrolysis of wheat flour (Nestlé 
Product Technology Centre Orbe, Orbe, Switzerland), which 
were used in a multicenter, open-label, OIT pilot study in 
children diagnosed with immunoglobulin E (IgE)-mediated 
wheat allergy. The study was conducted in Switzerland 
between 2011 and 2012.
Materials and Methods
The study product consisted of partially hydrolyzed wheat pro-
teins (8.8 g equivalent protein/100 g powder), carbohydrates, 
essential amino acids, fats, and vitamins, produced at the Nestlé 
Product Technology Centre Orbe.
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Hydrolysis of wheat proteins was assessed by size-exclusion 
chromatography performed by resuspending wheat flour or 
partially hydrolyzed wheat-based cereals (pHC) in 2% (v/v) 
acetonitrile/0.1% (v/v) formic acid and injection of the soluble 
fraction on a Superdex Peptide 10/300 GL column. 
Allergenicity of the pHC was assessed by gliadin quantifica-
tion (commercially available enzyme-linked immunosorbent 
assay [ELISA] kit optimized for raw and process foods matri-
ces [181GD; Morinaga, Tokyo, Japan]), recognition by anti-
bodies of specific wheat components (indirect ELISA) and by 
in vitro cross-linking activity, assessed by degranulation of rat 
basophilic leukemia cells (RBLs).
Subjects (2-12 years) with positive skin prick test (SPT) or 
positive specific IgE and immediate positive reaction to wheat 
(confirmed by a physician supervised standard OFC performed 
≤1 year before enrollment) or unequivocal history of an imme-
diate reaction to wheat suggestive of allergy were recruited. 
Skin prick tests were performed using a wheat extract from 
Allergopharma (Reinbek, Germany) and histamine control 
from ALK-Abello (Hørsholm, Denmark). The wheal size was 
calculated as (D + d) / 2, in which “D” is the longest diameter of 
the wheal, and “d” is the longest diameter orthogonal to D. A 
cutoff of ≥3 mm was used for a positive SPT. Wheat-specific 
IgE levels were determined using ImmunoCAP (Thermo 
Fisher, Uppsala, Sweden) according to the instructions of the 
manufacturer. Positive IgE levels were considered if >0.35 kU/L. 
Open food challenges were performed with wheat bread or 
wheat porridge in 2 centers and with commercial cooked Ebly 
(https://www.ebly.com/) in 1 center, following the routinely 
used protocol in the respective centers.
The OIT protocol included a 1-day initial escalation 
phase with pHC (maximum dose: 25 g, maximum cumula-
tive dose: 35.2 g), followed by a 1- to 6-month maintenance 
phase (Figure 1).
For the escalation phase, the product was prepared by recon-
stitution with water. Partially hydrolyzed wheat-based cereals 
were administered every 30 minutes with increasing doses as 
follows: step 1: 0.2 g (0.018 g equivalent protein), step 2: 2 g 
(0.18 g equivalent protein), step 3: 8 g (0.7 g equivalent pro-
tein), step 4: 25 g (2.2 g equivalent protein), for a total amount 
of 35.2 g (3.1 g equivalent protein). Both objective and subjec-
tive symptoms were recorded at each step.
Subjects having tolerated the maximum dose of pHC (25 g) 
entered the maintenance phase; subjects having an immediate 
allergic reaction to the study product during the first day were 
proposed to come back the day after to do a second escalation 
phase starting with the maximum dose tolerated during the 
first escalation phase. If the subject had a reaction with a cumu-
lative dose lower than 10.2 g, the subject was withdrawn. If the 
maximum cumulative dose tolerated was between 10.2 and 
35.2 g, the subject continued the protocol at home with the 
maximum dose of pHC given as the maintenance dose.
For the maintenance phase, the product was dissolved in 
water or mixed with other food well tolerated by the child. 
Parents were asked not to heat up the study product and to give 
it to the child in one serve every day until the final visit. 
Maintenance phase duration was encouraged up to 6 months, 
but shorter timing (1 month minimum) was accepted in case 
patients would like to stop for nontolerance, for example.
The primary end point was the presence or not of immedi-
ate adverse reactions to pHC during the initial escalation 
phase, with evaluation of the maximum dose tolerated. The 
secondary end points were compliance with product intake, 
morbidity as assessed by the frequency of adverse events, 
immunologic parameters (antibody response to wheat), and 
allergic reactions during the regular open food challenge test 
at final visit. The open food challenge test was conducted 
using Ebly, a wheat-based product commercialized in 
European countries such as Switzerland. Every 30 minutes, 
the product was administered with increasing doses as fol-
lows: step 1: 0.66 g Ebly (0.03 g protein), step 2: 2.2 g Ebly 
(0.1 g protein), step 3: 6.6 g Ebly (0.3 g protein), step 4: 22 g 
Ebly (1 g protein), and step 5: 66 g Ebly (3 g protein) (total 
amount of 4.43 g protein). Any occurrence of objective or 
Figure 1. Study protocol. IgE indicates immunoglobulin E; SPT, skin prick test.
aOnly for individuals without preliminary results for specific IgE sensitization to wheat ≤1 year before screening.
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persistent (45 minutes) subjective symptoms was considered 
as a positive result to the challenge test.
No inferential analysis was attempted for this trial, and 
therefore, all the analyses conducted were descriptive. Clinical 
research protocol was approved by the Ethical Review Board of 
Lausanne, CH (Commission cantonale d’éthique de la recherche 
sur l ’être humain, Ref. 297/10); Geneva, CH (Commission cen-
trale d’éthique de la recherche sur l ’être humain, Ref. 10-260); and 
Zürich, CH (Kantonale ethikkommission Zürich, Ref. 2010-
0218/2). All parents of enrolled subjects provided informed 
consent before the start of the study.
Results
Hydrolysis of wheat proteins was assessed by size-exclusion 
chromatography (Figure 2A). The low allergen content of 
pHC was shown by the level of gliadin, being the most aller-
genic wheat protein, (3.0 ± 1.3 mg/g protein), which was more 
than 500 times lower than gliadin levels in wheat flour 
(1655.9 ± 417.2 mg/g protein) (Figure 2B). The mediator 
release assays of RBLs showed a highly reduced gliadin-
induced degranulation capacity (>105-fold reduction) of pHC 
compared with both gliadin and wheat flour (Figure 2C). 
Epitopes from γ- and ω-gliadins (monoclonal antibodies used 
were directed against repeated and N-terminal sequences) and 
from low- and high-molecular-weight glutenins were not 
detectable in the pHC, whereas epitopes from the α-gliadins 
(C-terminal sequence) appeared to be more clearly recognized 
in the pHC than in the wheat extract. Finally, epitopes from 
lipid transfer protein (LTP) and α-amylase inhibitors were 
decreased in pHC but still present (Figure 3).
Nine children were enrolled in the trial (mean age: 
7.2 ± 3.23 years, 8 boys) (Table 1). Allergy assessment was 
done at inclusion; respiratory and food allergies other than 
wheat allergy were recorded (Table 1). Only 2 of the 9 patients 
described in the study were allergic to wheat only, 3 had res-
piratory allergy (to dust mite, pollen, and/or cat dander), and 
6 had allergy to other foods than wheat (including milk, egg, 
and nuts).
All had a clear history of IgE-mediated wheat allergy. An 
immediate positive reaction to wheat by OFC was confirmed 
in 6 of the 9 subjects within a year before enrollment; dose of 
the wheat-based product used for the challenge varied a lot 
between patients (Table 1) and no relation could be observed 
with the tolerance or not of the pHC during the initial escala-
tion phase. The 3 other patients presented high levels of wheat-
specific IgE (89, >100, and >100 kU/L, respectively) together 
with a convincing history at inclusion. Four (44%) showed 
allergic reactions after ingestion of pHC at the initial escala-
tion phase and OIT was not continued (Table 1). Allergic reac-
tions were typical manifestations of mild to severe wheat 
allergy (Table 1) and were successfully treated with antihista-
mines; no patient needed adrenaline. The 5 other patients tol-
erated the full dose of 25 g. Patients who passed the initial 
escalation phase tended to display lower wheat IgE levels at 
Figure 2. Peptide profile and allergenicity assessment of pHC compared with wheat. (A) Size-exclusion chromatography, (B) gliadin quantification using 
a commercial enzyme-linked immunosorbent assay kit and (C) in vitro 3H-serotonin release from anti-gliadin IgE-bearing rat basophilic leukemia cells 
(RBL-2H3 cell line) exposed to pHC, wheat flour, or gliadin. MW indicates molecular weight; pHC, partially hydrolyzed wheat-based cereals.
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inclusion in the trial than those who failed the tolerance test 
(Table 1). High levels of wheat IgE (≥100 kU/L), and possibly 
elevated levels of IgE to gliadin, appeared to be predictors of a 
clinical reaction to pHC. Immunoglobulin E to ω-5 gliadin 
and wheat LTP both appeared to be less predictive of clinical 
reactivity (Table 2). Of the 5 patients who tolerated the study 
Table 1. Clinical features and compliance data.
PATIENT AGE 
(Y)/
SEx
OTHER ALLERGIES 
THAN WHEAT 
ALLERGYa
MAxIMuM 
TOLERATED DOSE 
(FOOD CHALLENGE 
PRIOR TRIAL)
HIGHEST pHC 
DOSE TOLERATED 
DuRING INITIAL 
ESCALATION 
PHASE
HIGHEST INTENSITYb 
OF THE ALLERGIC 
REACTIONSc DuRING 
INITIAL ESCALATION 
PHASE
PATIENT COMPLIANCE
DAYS IN 
TRIAL
DAYS OFF THE 
PRODuCT (%)
Patients tolerating pHC
 1 7.4/m Mi, Fi, Nu 45 g wheat bread 25 nr 185 4 (2.2)
 2 10.7/m Fi, Po 20 g wheat porridge 25 nr 196 0.5 (0.3)
 3 11/m Mi, Eg, Po, DM, Ca nd 25 u2 186 1 (0.5)
 4 2.8/m None 2.8 g wheat bread 25 nr 155 2 (1.3)
 * 4.4/m Mi, Eg, Nu, Pe, Ba, 
DM, Po
30 mg wheat bread 25 nr 83 54 (65.1)
Patients not tolerating pHC
 5 4.6/m Eg nd 2 I1, C1, W1 1 0
 6 8.5/f Po nd 0.2 u2, R2, W3, H3, I1, B3 1 0
 7 4.7/m None 2.8 g wheat bread 2 V1, u2, S2, A2 1 0
 8 11.1/m Eg 58.5 g Ebly 8 I2, P1, T1 1 0
Abbreviations: f, female; LTP, lipid transfer protein; m, male; nd, not done; nr, no reaction; pHC, partially hydrolyzed wheat-based cereals.
a Allergy to Ba: banana, Ca: cat, DM: dust mite, Eg: egg, Fi: fish, Mi: milk, Nu: nuts, Pe: peanut, Po: pollens.
b Intensity of allergic reactions: (1) mild, (2) moderate, and (3) severe.
c Allergic reactions: u: urticaria, I: itching, C: coughing, W: wheezing, R: rhinitis, H: hoarseness, B: breathlessness, V: vomiting, S: sneezing, A: angio-edema, P: abdominal 
pain, T: chest tightness.
* Withdrew.
Figure 3. Recognition of specific wheat components in wheat flour and pHC. Intensity of response (expressed in optical density unit) in antigen-coated 
plate indirect enzyme-linked immunosorbent assay kit, using antibodies specific for several wheat allergens: α/β-gliadins, ω-2 and γ-gliadins, ω-5 gliadins, 
LTP (lipid transfer protein), AAI (α-amylase inhibitors), HMW-GS (high-molecular-weight glutenins), and LMW-GS (low-molecular-weight glutenins). Black 
and gray bars correspond to pHC and wheat flour, respectively. 
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product, 4 completed the trial, with strict compliance with 
product intake (155-196 days of product intake, corresponding 
to >97%; Table 1). One patient was withdrawn due to noncom-
pliance (83 days of product intake of the 137 days in the study, 
corresponding to 34.9%; Table 1). Most (60%) of the adverse 
events that occurred were unrelated to the study product, 16% 
were unlikely to be related, and 24% were probably related. 
Only 2 of the 5 patients who tolerated pHC and continued the 
trial through the maintenance phase at a dose of 25 g pHC had 
adverse events probably related to the study product. One 
patient had severe abdominal pain for 2 days (no medication 
prescribed) and 2 moderate eczema episodes (duration of 11 
and 8 days, respectively). Eczema was treated with oral and 
topical antihistamines and a topical calcineurin inhibitor. The 
other patient once had moderate urticaria lasting 1 day and was 
treated with oral antihistamines. No patient needed adrenaline. 
The 4 children who completed the study all successfully passed 
the wheat challenge test at the end of the study (commercially 
available wheat-based product [Ebly]) and could consume 60 
to 66 g of pHC (7.3-9.0 g equivalent hydrolyzed protein).
Discussion
In this pilot study, although nearly half of the study popula-
tion showed allergic reactions to the low-allergenic pHC 
during the initial challenge at V1 (primary outcome), the 
patients who completed the trial all successfully passed the 
wheat challenge test.
Characterization of the pHC showed that despite the nota-
ble reduction in gliadin content and gliadin-induced degranu-
lation capacity, certain wheat components remained sufficiently 
antigenic, and this may have caused the allergic reactions in the 
patients during the initial escalation phase. For this group of 
patients, such an initial day escalation with pHC might not be 
the best option for starting OIT. Characterization data of the 
pHC combined with the sensitization profile of patients could 
help selecting patients tolerating pHC and therefore eligible 
for OIT using pHC.
Another criteria to help predicting which patient would tol-
erate or not the pHC would be to relate it to the results of a 
wheat challenge prior to enrollment. However, due to the non-
harmonized protocols used to perform the OFCs in the differ-
ent centers before the trial and the few numbers of patients 
included, we cannot draw any conclusion from this trial.
The initial escalation phase for pHC conducted at V1 may 
have exerted similar effects to those of an ultra-rush induction 
phase for OIT, and this might have contributed to the benefi-
cial effects observed. The advantage of using pHC is the short 
time frame (1 day) required to reach the maintenance dose as 
compared with the updosing procedure used in most OIT pro-
tocols, which can take up to several months including several 
days in a medical facility.5,6 In the context of this pilot trial, we 
did not assess whether the patients who reacted to pHC at V1 
might have been able to reach the maintenance dose with more 
gradual increases in the dose administered.
Finally, as we did not compare the outcome of the initial 
escalation phase between intact wheat and pHC in similarly 
sensitized group of patients, we cannot answer the hypothesis 
that pHC is a better option for OIT than normal wheat flour.
One of the strengths of our study is the promising results 
regarding efficacy, yet to be confirmed in a larger placebo-con-
trolled study. However, we believe that the chances of natural 
outgrow were very low in our patients. Mean age of the chil-
dren at recruitment was 7.2 ± 3.23 years, which corresponds to 
the median age for resolution of wheat allergy described in lit-
erature,7 and the 4 subjects who tolerated wheat after the OIT 
were 7.4, 10.7-, 11-, and 2.8-year old at enrollment. In addi-
tion, some patients were highly allergic as shown by the low 
dose of wheat inducing allergic reaction during the wheat chal-
lenge performed within 1-year prior enrollment into the study.
One advantage of using pHC would be safety. No serious 
adverse event necessitating the use of epinephrine happened 
during the 1-day initial escalation phase. During the mainte-
nance phase, only 2 of the 5 patients had adverse events prob-
ably related to the study product.
Other promising wheat OIT studies have been published 
recently using different approaches to propose safer and effica-
cious treatment. Khayatzadeh et  al8 reported a study using 
bread in rush OIT (n = 8 anaphylactic patients, 5-7 years old) 
and outpatient protocol (n = 5 nonanaphylactic patients, 
5-19 years old). Despite similar limitations as our study (low 
number of patients, no placebo group, no food challenge at 
inclusion), all patients tolerated 5.2 g of wheat protein at the 
end the maintenance phase. All subjects enrolled successfully 
Table 2. Specific IgE levels.
PATIENT IgE LEVELS TO WHEAT PROTEINS (MEASuRED BY 
IMMuNOCAP, ku/L)
WHEAT GLIADIN w-5 GLIADIN WHEAT LTP
Patients tolerating pHC
 1 3.34 0.78 <0.35 1.49
 2 86.9 10.3 0.65 4.18
 3 89 24.7 2.08 <0.35
 4 0.41 <0.35 <0.35 <0.35
 * 15.85 3.43 <0.35 1.13
Patients not tolerating pHC
 5 >100 >100 5.51 35.4
 6 >100 >100 nm nm
 7 100 nm nm nm
 8 >100 22 0.38 0.62
Abbreviations: LTP, lipid transfer protein; nm, not measured; pHC, partially 
hydrolyzed wheat-based cereals.
* Withdrew.
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completed the build-up phase (several days or several weeks 
depending on the protocol) as compared with 56% in our study, 
suggesting that despite pHC is less allergenic than intact wheat 
protein, 1-day escalation phase was possibly too short for some 
of the patients. Severe symptoms during both build-up and 
maintenance phase needed the administration of epinephrine 
(in the anaphylactic group) and/or short-acting β-agonists in 
both groups in the study by Khayatzadeh et al. On the contrary, 
Rodriguez del Rio et al6 reported only mild adverse reactions 
during the dosing-up phase in 2 of the 6 patients, and only 1 of 
the 5 patients experienced a reaction during maintenance phase 
(generalized urticaria induced by exercise immediately after 
intake), whereas in our study, no rescue medication was needed. 
In the study by Rodriguez del Rio, patients were prescribed 
daily oral antihistamine during the updosing phase and the 
treatment was tapered over the first week of the maintenance 
phase, which could explain the only mild adverse events despite 
the use of intact protein in the protocol. Finally, a Japanese 
study using boiled udon as an alternative to intact wheat pro-
tein and combining a 5-day rush and a several months build-up 
phase before the maintenance phase reported 89% of success 
for desensitization and 61.1% of sustained unresponsiveness in 
patients with wheat-induced anaphylaxis.9 Despite the need to 
use intramuscular adrenaline to treat adverse reactions in a few 
patients, this study represents a promising alternative to the use 
of intact wheat protein for OIT.
In conclusion, our study does provide preliminary evidence 
that OIT using a low-allergenic pHC product is applicable in 
a “home setting” and thus a promising therapeutic option for 
wheat allergic patients who tolerate pHC. The limitations of 
our study inherent to a pilot study are the small sample size, 
which clearly limits the interpretation or generalization of the 
findings, and the lack of a placebo-controlled group.
Results have to be confirmed in a clinical setting including 
higher numbers of subjects and a placebo group. It also has to 
be confirmed whether the subpopulation that tolerates pHC 
and thus would profit from OIT could be identified by wheat-
specific IgE levels below 100 kU/L.
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